Loading ...

Patti Tosta

Immune Tolerance Network

Director, Research Operations

http://www.immunetolerance.org

Assessment Group

ptosta@immunetolerance.org

Work:

415-353-4421

Mobile:

415-353-1405

Address:

Immune Tolerance Network

Committees:

,

Studies:

ITN002AI

-

Treating Systemic Lupus Erythematosus (SLE) Patients with CTLA4-IgG4m

ITN003AI

-

ITN011AI

-

PsA Treatment With hOKT3γ1 (Ala-Ala)

ITN020AI

-

Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis

ITN021AI

-

Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis

ITN033AI

-

High Dose Immunosuppression and Autologous Stem Cell Transplantation for Multiple Sclerosis

ITN034AI

-

Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis

ITN035AI

-

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis

ITN037AI

-

ITN038AI

-

ITN047AI

-

A Study to Determine the Immunogenicity and Oral Tolerance to Keyhole Limpet Hemocyanin

ITN051AI

-

Defining Immune Tolerance in ANCA-associated Vasculitis

ITN055AI

-

Rituximab and Belimumab for Lupus Nephritis

ITN059AI

-

Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris

ITN075AI

-

Brentuximab Vedotin for Systemic Sclerosis

ITN077AI

-

Best Available Therapy Vs. Autologous Hematopoietic Stem Cell Transplant For MS

ITN080AI

-

Belimumab With Rituximab for Primary Membranous Nephropathy

ITN086AI

-

Evaluation of AMG 714 for Vitiligo

ITN091AI

-

VIBRANT: VIB4920 for Active Lupus Nephritis

ITN095AI

-

Siplizumab in T1DM

ITN505AI

-

Mechanistic Studies in a Phase II Trial of Multiple Sclerosis with Altered Peptide Ligand (APL)

ITN510AI

-

ITN511AI

-

ITN525AI

-

Gilead ITN525AI

ITN814AI

-

ITN815AI

-

Bio:

Admin Links

Shortcuts

ITN Documents

Links